阿拉丁(688179) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥98,473,575.99, representing a year-over-year increase of 13.79%[5] - The net profit attributable to shareholders was ¥17,107,659.32, showing a slight decrease of 0.84% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥16,787,774.31, reflecting a decrease of 2.84% year-over-year[6] - The total operating revenue for Q1 2024 was CNY 98,473,575.99, representing an increase of 13.5% compared to CNY 86,543,299.85 in Q1 2023[19] - The net profit for Q1 2024 was CNY 17,107,659.32, slightly down from CNY 17,251,791.95 in Q1 2023, reflecting a decrease of 0.8%[20] Cash Flow and Assets - The net cash flow from operating activities was ¥14,638,706.12, with no applicable year-over-year comparison[6] - The company's cash flow from operating activities for Q1 2024 is not provided, but the overall financial health appears stable based on the balance sheet data[22] - The company's cash and cash equivalents decreased to RMB 507,944,575.71 from RMB 522,535,290.62, representing a decline of about 2.25%[15] - The ending cash and cash equivalents balance was $507.94 million in Q1 2024, down from $532.21 million in Q1 2023[24] - The net cash flow from operating activities was $14.64 million in Q1 2024, a significant improvement from a negative $21.57 million in Q1 2023[24] Shareholder Equity and Assets - The total assets at the end of the reporting period were ¥1,501,760,226.33, a decrease of 0.25% from the end of the previous year[6] - The equity attributable to shareholders increased to ¥1,054,821,891.06, marking a growth of 1.78% compared to the previous year-end[6] - The total equity attributable to shareholders increased to CNY 1,054,821,891.06 in Q1 2024 from CNY 1,036,402,989.42 in Q1 2023, reflecting a growth of 1.8%[17] Research and Development - Research and development expenses totaled ¥14,095,847.62, accounting for 14.31% of operating revenue, a decrease of 0.66 percentage points[6] - Research and development expenses for Q1 2024 were CNY 14,095,847.62, compared to CNY 12,956,664.33 in Q1 2023, marking an increase of 8.8%[20] Liabilities and Financial Health - The total liabilities for Q1 2024 were CNY 446,938,335.27, down from CNY 469,150,626.28 in Q1 2023, showing a decrease of 4.7%[17] - The company's long-term equity investments decreased to RMB 2,457,428.83 from RMB 2,514,178.48, a decline of approximately 2.25%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,249[10] - There were no significant changes in the shareholder structure or related party transactions reported during the period[14] Market and Product Development - The company is focusing on expanding its market presence and developing new products, although specific details were not disclosed in the report[14]